Home Featured

Featured

Random

Video Roundtable: The Future of Ketamine Therapy

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

Question 4 Fails: Massachusetts Says No to State-Regulated Psychedelics Access and Decriminalisation

Psychedelic Education: Insights, Advice, and Where to Start

MAPS and Wesana Health Resume Negotiations

John C. Lilly: Father of LSD In the Sensory Deprivation Tank

PTSF88 – Dr. Ben Sessa of Awakn Life Sciences + Josh...

How Psychedelics Can Treat Eating Disorders

Mydecine Files MYCO-003 Final Patent Application and Reports Positive Preclinical Data

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

PsychCentral – Microdosing Psychedelics Linked to Lower Anxiety, Depression, Stress

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive...

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants...

Numinus Expands Research Capabilities with new Phoenix Clinical Research Site

12 3...315 Page 1 of 315

EDITOR PICKS

April 2026 Psychedelic Bill Round-up

Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future...

The War on Drugs Is a War On Mothers and Their...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.